Werewolf Therapeutics, Inc.

CAMBRIDGE, MA · Founded 2017 · CIK 0001785530 · Biotech · Public

Conditionally activated proinflammatory immune modulators for cancer treatment

werewolftx.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$104M
2 Form D · Jan 2021
69 months since last filing
Contracts
—
No federal contracts on record
Patents
40
12 granted · 28 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$31,572,600
Private capital raisedForm D · SEC$72,069,999
Form D · SECPress

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1441KJ BIOSCIENCES, LLC——
1442Centaurus Therapeutics, Inc.—$2.0M
1443ACUREX THERAPEUTICS CORPORATION——
1444Werewolf Therapeutics, Inc.—$104M
1445TRAILHEAD BIOSYSTEMS, INC.—$30M
1446Saliogen Therapeutics, Inc.—$94M
1447BRAINSTORM THERAPEUTICS, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Press

1 article · matched on company name

Founders & Team

From Form D filings · 10 related persons
  • Sakae AsanumaDirector
  • Patrick BaeuerleDirector
  • David CordoExecutive Officer
  • Derek DiRoccoDirector
  • Luke EvninDirector
  • Daniel HicklinDirector · Executive Officer
  • Alon LazarusDirector
  • Briggs MorrisonDirector
  • Elise WangDirector
  • Christoph WestphalDirector

Patents

USPTO · 12 granted of 40

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.